An adult with PTSD who started buspirone 5 mg and aripiprazole 5 mg daily four days ago now reports fluctuating high and low mood throughout the day—what is the likely cause and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mood Fluctuations After Starting Buspirone and Aripiprazole for PTSD

The fluctuating "high and low" mood is most likely caused by aripiprazole's partial dopamine agonist activity, which can produce paradoxical activation and agitation in PTSD patients, particularly within the first days of treatment. 1, 2

Likely Cause of Symptoms

Aripiprazole is the primary culprit for these mood fluctuations. The medication's unique mechanism as a dopamine D2 partial agonist can cause behavioral activation, agitation, and mood instability, especially early in treatment. 1, 2

  • Aripiprazole-induced activation and agitation occur in approximately 15.5% of patients, with symptoms appearing most commonly in the first 30 days of treatment. 3, 2
  • The 5 mg dose is relatively low, but adverse effects from aripiprazole's partial agonist properties are documented even at lower doses and can manifest as restlessness, mood swings, and subjective feelings of being "high." 2
  • Women experience aripiprazole adverse effects three times more frequently than men, which may be relevant depending on patient sex. 2

Buspirone is unlikely to be causing these specific symptoms. While buspirone can cause nervousness (4% incidence) and excitation (2% incidence), these are typically mild and do not present as fluctuating "high and low" mood states. 4

Immediate Management Steps

Discontinue aripiprazole immediately and reassess the patient's symptoms over 48-72 hours. Most aripiprazole-induced behavioral symptoms resolve within 30 days of discontinuation or dose reduction. 3

  • Monitor closely for resolution of mood fluctuations after stopping aripiprazole. 3
  • Continue buspirone at 5 mg if tolerated, as it has minimal adverse effects and may provide benefit for PTSD-related anxiety symptoms. 5, 4

Evidence-Based PTSD Treatment Alternatives

Neither buspirone nor low-dose aripiprazole represents guideline-based first-line treatment for PTSD. 6, 7

For core PTSD symptoms, initiate sertraline 25 mg daily, titrating to 150-200 mg over 4-6 weeks. SSRIs are the only FDA-approved medications for PTSD with proven efficacy. 7

For PTSD-related nightmares specifically:

  • Start prazosin 1 mg at bedtime, titrating by 1-2 mg every few days to effective doses of 3-15 mg/day based on blood pressure tolerance. 6, 7
  • Alternative options include trazodone 25-50 mg at bedtime or clonidine 0.1 mg twice daily if prazosin is ineffective or not tolerated. 6, 7

If aripiprazole was being used for nightmare treatment: The recommended dose for nightmares is 15-30 mg/day, not 5 mg, and it is considered a third-line option only after prazosin, clonidine, and risperidone have failed. 6

Critical Clinical Pitfalls

  • Do not continue aripiprazole at 5 mg for PTSD. This dose is subtherapeutic for any indication and increases the risk of activation without therapeutic benefit. 6, 8
  • Do not use benzodiazepines for chronic PTSD management despite patient distress, as they lack efficacy for core PTSD symptoms and carry dependence risk. 7
  • Monitor for impulsive-compulsive behaviors if aripiprazole is ever reintroduced, including gambling, hypersexuality, and compulsive shopping, which can emerge within 30 days of starting treatment. 3
  • Avoid combining multiple serotonergic agents (buspirone + SSRI) initially without careful monitoring for serotonin syndrome. 7

References

Guideline

Mechanism of Action and Clinical Benefits of Aripiprazole

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Review of the side-effect profile of buspirone.

The American journal of medicine, 1986

Guideline

Treatment of Nightmares in PTSD and Nightmare Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of PTSD with Active Suicidality

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.